GLP-1 RECEPTOR AGONISTS: THE REVOLUTION IN COMBATING OBESITY

A prolonged feeling of fullness that allows for effortless reduction in food intake

Obesity is a significant public health issue, projected to affect more than half of the global population by 2035¹. Recent advances in medical treatments for obesity include the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have shown promising results in managing this condition.^2,3

Clinical studies have demonstrated that GLP-1 RA therapy can lead to significant weight loss, often exceeding 15%. GLP-1 RAs help regulate appetite and digestion by slowing gastric emptying. This prolongs the feeling of fullness, naturally reduces appetite, and helps individuals eat less by decreasing cravings and the need for snacking. This mechanism facilitates weight loss without the need for restrictive diets or constant self-monitoring.^3,4

In addition to weight loss, these medications have been shown to improve cardiovascular health, increase insulin sensitivity, and enhance blood sugar control. These benefits are particularly valuable in managing type 2 diabetes and reducing the risk of associated complications.^2,3

GLP-1 RA medications are accompanied by side effects

Despite GLP-1 RAs representing a promising therapy for addressing obesity, they pose side effects that can present significant nutritional challenges during the weight loss process. Muscle loss, which may account for a substantial portion of the total weight lost, can risk sarcopenia. This condition can make daily activities more effortful and contribute to fatigue. Additionally, reduced caloric intake may lead to nutritional deficits. Patients may also experience common gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. ^3-7

Given these side effects, it is crucial to ensure that patients’ nutritional needs are fully met. This includes careful monitoring to prevent muscle mass loss and deficiencies in essential nutrients, ensuring a safe and effective approach to obesity treatment with GLP-1 RAs.

References:

1. World Obesity Federation. World Obesity Atlas 2024
2. Melson E, et al. Int J Obes (Lond). 2024;48(2):220-230
3. Wadden TA, et al. Curr Obes Rep. 2023;12:453-473
4. Christensen S, et al. Obes Pillars. 2024;11:100121
5. Wang JY, et al. Front Endocrinol (Lausanne). 2023;14:1085799
6. Prado CM, et al. Lancet Diabetes Endocrinol. 2024 Nov;12(11):785-787
7. Neeland IJ, et al. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27